


## POLYNUCLEAIRES -PROTHESE ARTICULAIRE

DESC, Maladies Infectieuses  
Bégin, 04.10.2004

Louis Bernard,  
Division des Maladies Infectieuses  
& Département d'Orthopédie

### Prothèse de hanche: composants



Tête céramique

Cupule titane et polyéthylène

Ciment méthyl-méthacrylate

Tige alliage chrome-cobalt

### Natural history of prosthetic implant (1)

- 1 Implantation of joint prosthesis
- 2 Follow-up (5-30 years)
  - without complication (70-75%)
  - complication (25-30%)
    - » aseptic loosening » 20-25%
    - infection 1-2%
    - other complications 5%
- 3 Death of patient (no further complications!)

### Natural history of prosthetic implant (2)


Complications after 1,434 Charnley arthroplasties, follow-up 33 years

| During follow-up                            | N   | %    |
|---|-----|------|
| Dislocation                                 | 24  | 1.7  |
| Deep infection                              | 24  | 1.7  |
| Loose cup                                   | 261 | 18.2 |
| Loose stem                                  | 93  | 6.3  |
| Fractured stem                              | 25  | 1.7  |
| Other (including trochanteric explorations) | 69  | 4.8  |
| Unexplained pain                            | 3   | 0.2  |

1.7% **Infection**  
22.5% **Loosening**

Wroblewski BM, JBJS Br 2002.

### When does prosthetic infection occur ?




**Type I**  
Acute and early just after surgery (< 1 m)

**Type II**  
Chronic and later prosthesis with pain

**Type III:**  
Acute and late hematogenous route prosthesis without pain

### ACTUAL PATHOPHYSIOLOGICAL HYPOTHESES OF PROSTHETIC JOINT INFECTION (1)




The Small Colonies Variant (SCV)



The BIOFILM

sanctuary for bacteria (CEMENT)


**OTHER PATHOPHYSIOLOGICAL HYPOTHESES OF PROSTHETIC JOINT INFECTION (1)**




**GRANULOMA**



**QUESTION ?**



**Aseptic Loosening (macroscopic analysis)**



**1ère étape**


**Analyse du tissu périprothétique *in vivo***

- ⇒ Biopsie per opératoire / descellement
  - fixation
  - microscopie électronique

**Aseptic Loosening  
(microscopic analysis)**


Hip  
neocapsule

Polyethylene  
particles




MEB x 695

Particules de polyéthylène - tissu périprothétique *in vivo*



Les PARTICULES de HDPE *in vivo* (MEB)




**2ème étape**

**Fabrication de particule de PEHD *in vitro***


⇒ **difficultés majeures de production de PEHD :**

- poudre primaire ≠ poudre secondaire
- taille < 1µm
- nombre nécessaire de PE pour expérience > 10<sup>6</sup>/ml
- reproductibilité
- propriétés physiques *in vivo* ≠ *in vitro*


Particules de HDPE *in vitro* (MO)




Particules de HDPE *in vitro* (MEB)



Particules de HDPE *in vitro* (MEB)



Particules de HDPE *in vivo* (MEB)




### 3ème étape


#### Tests de phagocytose

- l'effet dose/taille des particules de PEHD
- l'influence de la nature de la particule
- mécanisme de phagocytose
- tests fonctionnels


### Rappel




### Test de « killing bactérien »






### « Killing » de *S.aureus* par les polynucléaires en présence de particules de PE HD (0.22-50 µm)



**Killing » de *S.aureus*  
par les polynucléaires en présence de PEHD  
de CONCENTRATIONS DIFFERENTES**




**« Killing » de *S.aureus*  
par les polynucléaires en présence de particules  
de STRUCTURES DIFFERENTES**





**Complément**

- majoration de la dose de sérum humain 5-10-20% : idem
- dosage du complément Avant-après phagocytose: N
- Anticorps anti-récepteurs : normaux





# Phagocytose

- inhibition extra ou intra cellulaire ?
- phagocytose sélective ?



## Test de fonctionnalité du métabolisme oxydatif des polynucléaires et la dégranulation


- test qualitatif: NBT test MPO: myéloperoxydase
- tests quantitatifs: production de superoxyde
  - f-MLP (N-Formyl-Met-Leu-Phe)
  - PMA (Phorbol 12-Myristate 13-Acetate)







4ème étape

Confrontation clinique  
avec étude in vivo  
de polynucléaires périprothétiques  
d'une prothèse infectée

Polynuclear neutrophils  
from Aseptic Loosening  
(microscopic analysis)



Macrophages  
from Septic Loosening  
(microscopic analysis)



### DISCUSSION (1)

Prosthetic loosening and infection

Tunney (JCM 1999)

Revision of 120 prosthetic hip implants

Standard culture 22%

Bacterial 16S rRNA gene 72% ?

Often *Propionibacterium acnes* or CNS

What is the reality ?

### DISCUSSION (2)

The different hypotheses such as small colonies variant, biofilm, and sanctuary for bacteria, are probably not the only mechanism responsible for infection of a prosthesis.

How can salvage of a prosthesis, or a one-stage exchange, be effective in the presence of bacteria ?

### CONCLUSION(1)

A correlation between different factors :

wear of the prosthesis

bacteria

host response

seems to be present

### CONCLUSION(2)

The difficulty is to know exactly

•Are bacteria present so frequently ?

•What is the implication of bacteria in the host reaction to small or large particles ?

•When do bacteria arrive during the loosening of a prosthesis ?